Omada Health reported Q4 2025 revenue of USD 76 million, up 58%, and FY 2025 revenue of USD 260 million, up 53%. Q4 net income was USD 5 million and FY net loss was USD 13 million. Adjusted EBITDA was USD 8 million in Q4 and USD 6 million for FY 2025. Gross margin was 71% in Q4 and 66% for FY 2025, while non-GAAP gross margin was 73% in Q4 and 68% for FY 2025. Cash and cash equivalents totaled USD 222 million, and total members were 886,000 at year-end, up 55%. On the business side, Omada Health said it has supported more than 150,000 members on GLP-1s and announced GLP-1 Flex Care, an option designed to connect eligible employees with clinical evaluation, prescribing, and ongoing medical oversight for GLP-1s alongside Omada’s lifestyle and behavioral support. The company also highlighted 2025 launches of OmadaSpark and Meal Map, AI-powered tools for wellness education, and noted that in February 2026 it announced Omada for Cholesterol. For FY 2026, Omada Health forecast revenue of USD 312 million to USD 322 million and adjusted EBITDA of USD 7 million to USD 15 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omada Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-015153), on March 05, 2026, and is solely responsible for the information contained therein.